ABSTRACT
Objective High frequency oscillations (HFOs) recorded from intracranial electrodes during epileptiform discharges have been proposed as a biomarker of epileptic brain sites and may also be a useful feature for seizure forecasting, with mixed results. Currently, pathological subclasses of HFOs have been defined primarily by frequency characteristics. Despite this, there has been limited investigation into the spatial context of HFOs with recruitment of local cortex into seizure discharging. We sought to further understand the biophysical underpinnings of ictal HFOs.
Methods Here we examine ictal HFOs from multi-scale electrophysiological recordings during spontaneous human rhythmic onset seizures. We compare features of ictal discharges in both the seizure core and penumbra, as defined by multiunit activity patterns.
Results We show marked differences in spectral features, unit coupling, and information theoretic characteristics of HFOs during ictal discharges before and after local seizure invasion. Furthermore, we tie these timing-related differences to different spatial domains of seizures, showing that eccentric, penumbral discharges are widely distributed and less useful for seizure localization, which may explain the variable utility of HFOs in seizure localization and forecasting.
Interpretation We thus identify two distinct classes of ictal HFOs, implying two different mechanisms underlying pathological HFOs with contrasting significance for seizure localization.
Competing Interest Statement
Dr. Rolston reports personal fees from Medtronic, personal fees from NeuroPace, Dr. Friedman reports grants, non-financial support and other from Epilepsy Study Consortium, personal fees and other from Eisai, personal fees from Penumbra, grants, personal fees and other from Neuropace, grants from Epitel, grants and other from Empatica, grants and personal fees from UCB, Inc, other from Acorda Pharmaceuticals, grants and other from Adamas Pharmaceuticals, other from Alexza, other from Axcella, other from Biogen, other from Biopharm, other from CuroNZ, other from Engage, other from GW Pharma, other from Pfizer, other from Pfizer-Neusentis, other from Marinus, other from SK Life Sciences, other from Upsher Smith, other from Zogenix, other from Zynerba, other from Neuroview Technology, other from Receptor Life Sciences, other from Medtronic, Inc, other from Xenon pharmaceuticals, outside the submitted work; and Dr. Friedman serves on the editorial board of epilepsy.com and is a member of the executive committee of the physician advisory board of the Epilepsy Foundation of America. Dr. McKhann reports personal fees from Koh Young Inc. Dr. Doyle reports non-financial support and other from Neuroview Technology.
Funding Statement
This work was supported by NIH S10 OD018211 (CAS), NIH R01 NS084142 (CAS), NIH R01 NS095368 (CAS), NIH R21 NS113031 (JDR), and NIH KL2 TR002539 (JDR).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All analyses code are publicly available and data may be shared with the approval of the Columbia University Medical Center Institutional Review Board
